What is the strike price of the granted options and how does it compare to the current market price? | ATXS (Aug 06, 2025) | Candlesense
ATXS

What is the strike price of the granted options and how does it compare to the current market price?

Answer

The press‑release excerpt you provided does not disclose the strike price (exercise price) of the 180,000 stock options that Astria Therapeutics granted on August 1 2025. Because the strike price is not mentioned, we cannot directly compare it to the current market price of Astria Therapeutics’ common stock.

What this means for you

Item Information from the release What we still need to know
Number of options granted 180,000 shares under the 2022 Inducible Stock Incentive Plan –
Strike (exercise) price Not specified The exact dollar amount per share at which the options can be exercised
Current market price Not provided in the release The latest trading price of ATXS on Nasdaq (or other exchange) on the date you are asking about

How to obtain the missing data

  1. Full press release – The complete Business Wire announcement (often available on Astria’s Investor Relations website or the Business Wire archive) typically lists the strike price for each option grant. Look for a section titled “Option Grant Details” or a table that includes “Strike Price” and “Fair Market Value”.

  2. SEC filings – Companies often file a Form 8‑K or Form 4 with the SEC when they issue stock options. Those filings include the terms of the award, including the exercise price. You can search the SEC’s EDGAR database for Astria Therapeutics (ticker ATXS) around the August 1 2025 grant date.

  3. Market data – To compare the strike price to the current market price, you’ll need the latest trading price of ATXS. This can be obtained from:

    • Real‑time market data providers (e.g., Bloomberg, Reuters, Yahoo! Finance).
    • Nasdaq’s official website (nasdaq.com) by entering the ticker ATXS.
    • Your brokerage platform’s quote screen.

Example of how the comparison works (illustrative)

If the full release indicated, for instance, a $2.00 strike price and the current market price of ATXS is $3.50, the options would be “in‑the‑money” by $1.50 per share:

Metric Value (example)
Strike price $2.00 per share
Current market price $3.50 per share
Intrinsic value per option $3.50 – $2.00 = $1.50
Potential upside 75% above strike ([$1.50 / $2.00] × 100)

Until the exact strike price is known, any such calculation remains speculative.

Bottom line

  • Strike price: Not disclosed in the excerpt you shared.
  • Current market price: Not provided in the excerpt; you’ll need to look up the latest ATXS price on Nasdaq.
  • Action: Retrieve the full press release or the relevant SEC filing to obtain the strike price, then check a reliable market source for the current share price. Once both figures are in hand, you can directly compare them to assess whether the options are “in‑the‑money,” “at‑the‑money,” or “out‑of‑the‑money.”

Other Questions About This News

What percentage of ownership could the option recipients potentially hold if all options are exercised? When are the vesting periods and expiration dates for these options? Are there any anti‑dilution provisions or protective clauses tied to these options that could impact future financing activities? Are there any lock‑up or resale restrictions associated with the options once exercised? Could the exercise of these options provide additional funding for upcoming clinical trials or pipeline milestones? How does the size of this grant (180,000 shares) compare to the company’s average daily trading volume? How does this inducement grant compare in size and terms to recent grants by competitors in the biotech sector? How many total shares will be outstanding after the grant and potential exercise of these options? How might the market react to the increased potential float from this option grant? Is there a historical pattern of stock price movement around similar equity incentive announcements for Astria Therapeutics? What are the tax implications for the option recipients and could that affect the timing of exercises? What is the strategic rationale behind targeting non‑employee individuals with this inducement plan? Will the issuance of these options lead to significant dilution for existing shareholders? Will the grant affect the company’s ability to meet Nasdaq’s listing requirements in the near term?